BioCryst Pharmaceuticals | BCRX - Ebit



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.8B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


Ebit 更改 日
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Chugai Pharma JPY 158.77B 10.24B 2026-03
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
DBV Technologies USD -34.28M 6.83M 2025-09
Enanta Pharmaceuticals USD -23.54M 6.31M 2024-12
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 344.17M 39.71M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novavax USD 20.94M 100.32M 2025-12
PTC Therapeutics USD 45.89M 127.51M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 2.1B 2025-12
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03